Why This Guidance Matters
Medical devices vary widely in complexity, use environments, and maintenance needs. Many are reusable and require regular servicing to remain safe and effective. However, confusion has persisted around when servicing crosses the line into remanufacturing—a distinction that carries significant regulatory implications.
To address this, the U.S. Food and Drug Administration (FDA) has issued updated guidance to help stakeholders determine whether their activities qualify as remanufacturing and to clarify the associated regulatory responsibilities.
Servicing vs. Remanufacturing: What’s the Difference?
- Servicing refers to maintenance or repair that restores a device to its original safety and performance specifications without changing its intended use.
- Remanufacturing, on the other hand, involves changes that significantly alter the device’s performance, safety specifications, or intended use.
Understanding this distinction is critical for original equipment manufacturers (OEMs), independent service organizations (ISOs), and healthcare facilities that perform device maintenance.
What’s New in the Final Guidance
The updated guidance includes:
- A clearer definition of remanufacturing activities
- A new section outlining regulatory requirements for remanufacturers
- Labeling recommendations to ensure continued device safety and effectiveness
- References to FDA-recognized consensus standards and how to use them in regulatory submissions
The FDA emphasizes that this guidance is non-binding but reflects the agency’s current thinking and best practices.
Why Labeling Matters
For devices intended to be serviced over their useful life, the FDA recommends including in labeling:
- Key safety and performance specifications
- Troubleshooting steps
- Electrical and physical characteristics
- Precautionary information related to servicing
- Software version and release numbers
These details help ensure that servicing is performed correctly and that the device continues to meet its intended performance standards.
Compliance Considerations for Stakeholders
Entities performing remanufacturing must:
- Register their facilities with the FDA
- Comply with Quality System Regulations (QSR)
- Undergo FDA inspections under the same risk-based framework as OEMs
The guidance also encourages OEMs to provide sufficient information to support safe servicing—without requiring disclosure of proprietary or confidential data.
📚 Supporting Resources
Final Thoughts: Clarity That Drives Compliance
The FDA’s updated guidance brings much-needed clarity to the medical device servicing ecosystem. By clearly defining remanufacturing and outlining regulatory expectations, the agency empowers stakeholders to maintain compliance while ensuring patient safety.
Whether you’re an OEM, ISO, or healthcare provider, now is the time to review your servicing protocols, update labeling, and assess whether your activities fall under remanufacturing. Staying informed and proactive is the key to navigating this evolving regulatory landscape.